New developments in antifungal therapy: Fluconazole, itraconazole, voriconazole, caspofungin;Nieuwe ontwikkelingen in de antifungale therapie: Fluconazol, itraconazol, voriconazol, caspofungine

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 34, 2004, Pages 1679-1684

  Van 'T Wout, J W ^a   Kuijper, E J ^b   Verweij, P E ^b,c   Kullberg, B J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Afd Medische Microbiologie ^*

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ASTEMIZOLE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; DEXAMETHASONE; EFAVIRENZ; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; NEVIRAPINE; PHENYTOIN; QUINIDINE; RAPAMYCIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; CLINICAL TRIAL; DRUG CHOICE; DRUG COST; DRUG INDICATION; HEALTH CARE COST; HUMAN; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; REVIEW; SIDE EFFECT;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG CARRIERS; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MYCOSES; PEPTIDES; PEPTIDES, CYCLIC; PYRIMIDINES; SPECIES SPECIFICITY; TREATMENT OUTCOME; TRIAZOLES;

EID: 4344669881     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Wout JW van 't, Kullberg BJ, Meis JFGM, Reiss P. Schimmel-infecties bij patiënten met een gestoorde afweer. Ned Tijdschr Geneeskd 1995;139:1430-6.
2. Rex JH, Bennett JE, Sugar AM, Pappas PG, Horst CM van der, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
3. Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997;16:337-45.
4. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72.
5. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89.
6. Kullberg BJ, Pappas P, Ruhnke M, Viscoli C, Rex JH, Schlamm H, et al. Voriconazole compared to a strategy of amphotericin B followed by fluconazole for treatment of candidemia in non-neutropenic patients. Clin Microb Infect 2004;10(Suppl 3):s41.
7. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
8. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-18.
9. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001;33:e83-90.
10. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000;30:696-709.
11. Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003;348:2416-22.
12. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. N Engl J Med 2002;347:408-15.
13. Maertens J, Boogaerts M. Caspofungin in the treatment of candidosis and aspergillosis. Int J Infect Dis 2003;7:94-101.
14. Leenders ACAP, Daenen S, Jansen RLH, Hop WC, Lowenberg B, Wijermans PW, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998;103:205-12.
15. Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, Johnson PC, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999;28:291-6.
16. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-8.
17. Oude Lashof AML, Kullberg BJ. Amfotericine B: het einde van een tijdperk. Ned Tijdschr Geneeskd 2004;148:1665-8.
18. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 2003;36:1221-8.
19. Jacobs S, Price Evans DA, Tariq M, Al Omar NF. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit Care Med 2003;31:1938-46.
20. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001;135:412-22.
21. Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997;157:1857-62.
22. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000;342:756-62.
23. Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 2002;11:409-29.
24. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-55.
25. Wood N, Tan K, Purkins L, Layton G, Hamlin J, Kleinermans D, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003;56 Suppl 1:56-61.
26. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
27. Baede-van Dijk PA, Graeff PA de, Lekkerkerker JFF. De rol van cytochroom-P450-enzymen bij geneesmiddeleninteracties. Ned Tijdschr Geneeskd 1999;143:2607-11.
28. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
29. Hua G, Pennesi M, Shah K, Qiao X, Hariprasad SM, Mieler WF, et al. Safety of intravitreal voriconazole: electroretinographic and histopathologic studies. Trans Am Ophthalmol Soc 2003;101:183-9.
30. Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother 2002;49:889-91.
31. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-6.
32. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002;46:739-45.
33. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, Nubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002;46:451-7.
34. Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51.
35. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36:1445-57.
36. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002;35:982-9.
37. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997;41:1392-5.